Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
Want to see SE:XBRANE full AI Analyst Report?
XBRANE Stock Chart & Stats
kr10.37
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr10.37
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr5.42 - kr38.03
Previous CloseN/A
Volume1.93M
Average Volume (3M)117.17K
Market Cap
kr212.24M
Enterprise Valuekr117.36M
Total Cash (Recent Filing)kr66.75M
Total Debt (Recent Filing)kr56.88M
Price to Earnings (P/E)2.0
Beta0.99
Next Earnings
Jul 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)11.99
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-61.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.94
Revenue Forecast (FY)kr183.00M
Bulls Say, Bears Say
Bulls Say
Conservative Leverage And Equity CushionA low debt-to-equity (~0.10x) and sizable equity position provide durable financial flexibility for a biotech with ongoing R&D and clinical spend. This reduces near-term refinancing risk, supports continued program funding, and gives time to reach milestones before needing dilutive financing.
In-house Biologics Development And Manufacturing CapabilityOwning process development and manufacturing capabilities is a structural advantage: it lowers dependency on external CMOs, accelerates clinical material supply, and enables service revenue. Over months, this capability supports execution, partnerability, and margin control for biosimilar programs.
Diversified Commercial Model: Partnerships Plus Service RevenueA two-pronged revenue model — milestone/royalty-based partnering plus development/manufacturing services — reduces binary program risk and creates multiple funding pathways. Structurally, this supports steadier funding and potential upside from partner commercialization success.
Bears Say
Material Negative Operating Cash Flow And Free Cash FlowSustained negative operating and free cash flow implies ongoing reliance on external financing or milestone payments to fund operations. Over 2–6 months this raises dilution and refinancing risk, constrains discretionary R&D or manufacturing expansion, and limits ability to self-fund commercialization.
Sharp Revenue Decline And Top-line VolatilityA ~50% TTM revenue decline and historical volatility hinder forecasting and weaken negotiating leverage with partners. Structural instability in top-line receipts increases dependence on intermittent milestone payments and complicates long-term planning for manufacturing capacity and commercial launches.
Operating Losses And Earnings Quality ConcernsPersistent negative EBIT despite decent gross margin signals operating cost pressure or underutilized capacity. Reported net income appears supported by non-operating items, so core profitability and cash conversion remain weak, reducing confidence in sustainability of reported earnings.
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr5.42 and its highest was kr38.03 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr212.24M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is Jul 17, 2026 which is in 36 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on May 05, 2026. The company reported -kr0.634 earnings per share for the quarter, missing the consensus estimate of -kr0.52 by -kr0.114.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr0.634 in its last earnings report, missing expectations of -kr0.52. Following the earnings report the stock price went down -1.619%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ranibizumab biosimilar presently undergoing pivotal Phase III clinical trials. This therapeutic candidate is being evaluated for the treatment of several serious eye conditions, including wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. In its earlier, preclinical stages, Xbrane is progressing a range of biosimilars: Xcimzane: Targeting autoimmune diseases such as rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, psoriasis, and Crohn's disease. Xoncane: Designed for acute lymphocytic leukemia. Spherotide: Intended for prostate cancer, breast cancer, endometriosis, and uterine myoma. Xdivane: Developed for various cancers, including melanoma, lung cancer, head and throat cancer, bladder cancer, urinary tract cancer, and renal cell carcinoma. Moreover, Xbrane has established a strategic partnership with STADA Arzneimittel AG. This collaboration aims to explore and potentially pursue joint development and commercialization opportunities for its preclinical biosimilar candidates, Xcimzane and Xdivane.
Technical Analysis
Ascelia Pharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Active Biotech AB
―
Immunicum AB
―
Options Prices
Currently, No data available
---